Cancer Genetics Company Profile (NASDAQ:CGIX)

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics logoCancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CGIX
  • CUSIP: N/A
  • Web: www.cancergenetics.com
Capitalization:
  • Market Cap: $75.61 million
  • Outstanding Shares: 18,903,000
Average Prices:
  • 50 Day Moving Avg: $3.91
  • 200 Day Moving Avg: $2.53
  • 52 Week Range: $1.10 - $5.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 44.44
  • P/E Growth: -0.11
Sales & Book Value:
  • Annual Revenue: $27.95 million
  • Price / Sales: 2.71
  • Book Value: $1.11 per share
  • Price / Book: 3.60
Profitability:
  • EBIDTA: ($11,980,000.00)
  • Net Margins: -74.07%
  • Return on Equity: -63.26%
  • Return on Assets: -40.91%
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 2.50%
  • Quick Ratio: 2.50%
Misc:
  • Average Volume: 505,819 shs.
  • Beta: 1.44
  • Short Ratio: 6.21
 

Frequently Asked Questions for Cancer Genetics (NASDAQ:CGIX)

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How were Cancer Genetics' earnings last quarter?

Cancer Genetics Inc (NASDAQ:CGIX) issued its quarterly earnings results on Thursday, May, 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.07. The business had revenue of $7 million for the quarter, compared to the consensus estimate of $7.62 million. Cancer Genetics had a negative return on equity of 63.26% and a negative net margin of 74.07%. The firm's quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.39) earnings per share. View Cancer Genetics' Earnings History.

Where is Cancer Genetics' stock going? Where will Cancer Genetics' stock price be in 2017?

2 equities research analysts have issued 1-year price targets for Cancer Genetics' stock. Their predictions range from $6.00 to $6.00. On average, they expect Cancer Genetics' share price to reach $6.00 in the next year. View Analyst Ratings for Cancer Genetics.

Who are some of Cancer Genetics' key competitors?

Who owns Cancer Genetics stock?

Cancer Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (0.00%), Renaissance Technologies LLC (2.37%), Vanguard Group Inc. (1.69%), Fairbanks Capital Management Inc. (1.23%), EAM Investors LLC (0.62%) and Wedbush Securities Inc. (0.46%). Company insiders that own Cancer Genetics stock include Edward J Sitar, Geoffrey E Harris, John Pappajohn, Panna Sharma and Raju SK Chaganti. View Institutional Ownership Trends for Cancer Genetics.

Who sold Cancer Genetics stock? Who is selling Cancer Genetics stock?

Cancer Genetics' stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Wedbush Securities Inc.. View Insider Buying and Selling for Cancer Genetics.

Who bought Cancer Genetics stock? Who is buying Cancer Genetics stock?

Cancer Genetics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, EAM Investors LLC, Vanguard Group Inc., Geode Capital Management LLC, Bank of Montreal Can and KCG Holdings Inc.. Company insiders that have bought Cancer Genetics stock in the last two years include Geoffrey E Harris, John Pappajohn and Panna Sharma. View Insider Buying and Selling for Cancer Genetics.

How do I buy Cancer Genetics stock?

Shares of Cancer Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cancer Genetics stock cost?

One share of Cancer Genetics stock can currently be purchased for approximately $4.00.

Analyst Ratings

Consensus Ratings for Cancer Genetics (NASDAQ:CGIX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (50.00% upside)

Analysts' Ratings History for Cancer Genetics (NASDAQ:CGIX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/27/2017HC WainwrightReiterated RatingBuy$6.00HighView Rating Details
9/26/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
3/15/2016AegisBoost Price TargetBuy$8.00 -> $15.00N/AView Rating Details
3/11/2016Janney Montgomery ScottReiterated RatingBuy -> NeutralN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Cancer Genetics (NASDAQ:CGIX)
Earnings by Quarter for Cancer Genetics (NASDAQ:CGIX)
Earnings History by Quarter for Cancer Genetics (NASDAQ:CGIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.18)($0.11)$7.62 million$7.00 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.22)($0.15)$7.10 million$7.23 millionViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)$6.93 million$6.80 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.28)$6.50 million$7.00 millionViewN/AView Earnings Details
5/10/2016Q1($0.43)($0.39)$6.95 million$6.10 millionViewListenView Earnings Details
3/10/2016Q415($0.46)($0.48)$7.00 million$5.50 millionViewListenView Earnings Details
11/10/2015Q315($0.49)($0.56)$5.13 million$4.00 millionViewListenView Earnings Details
8/11/2015Q215($0.50)($0.51)$4.67 million$4.20 millionViewListenView Earnings Details
5/12/2015Q115($0.54)($0.43)$3.91 million$4.40 millionViewListenView Earnings Details
3/12/2015Q414($0.52)($0.49)$3.70 million$4.00 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.51)($0.41)$3.11 million$3.22 millionViewN/AView Earnings Details
8/14/2014Q214($0.39)($0.50)$2.13 million$3.20 millionViewN/AView Earnings Details
5/15/2014Q114($0.29)($0.27)$2.17 million$1.40 millionViewN/AView Earnings Details
3/26/2014Q4 13($0.36)($0.37)$1.95 million$1.90 millionViewN/AView Earnings Details
11/13/2013Q313($0.71)($0.61)$1.60 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cancer Genetics (NASDAQ:CGIX)
2017 EPS Consensus Estimate: ($0.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cancer Genetics (NASDAQ:CGIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cancer Genetics (NASDAQ:CGIX)
Insider Ownership Percentage: 25.40%
Institutional Ownership Percentage: 12.60%
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)
Institutional Ownership by Quarter for Cancer Genetics (NASDAQ:CGIX)
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Geoffrey E HarrisDirectorBuy2,500$3.75$9,375.00View SEC Filing  
12/14/2016Geoffrey E HarrisDirectorBuy2,500$1.50$3,750.00View SEC Filing  
11/28/2016John PappajohnDirectorBuy100,000$1.45$145,000.00View SEC Filing  
11/16/2016Edward J SitarCFOSell3,333$1.56$5,199.48View SEC Filing  
11/14/2016John PappajohnDirectorBuy31,100$1.48$46,028.00View SEC Filing  
8/16/2016John PappajohnDirectorBuy45,000$2.29$103,050.00View SEC Filing  
8/15/2016John PappajohnDirectorBuy147,500$2.16$318,600.00View SEC Filing  
3/17/2016John PappajohnDirectorBuy50,000$2.64$132,000.00View SEC Filing  
3/17/2016Panna SharmaCEOBuy1,500$2.59$3,885.00View SEC Filing  
3/16/2016John PappajohnDirectorBuy100,000$2.53$253,000.00View SEC Filing  
3/15/2016Panna SharmaCEOBuy1,000$2.56$2,560.00View SEC Filing  
8/27/2015John PappajohnDirectorBuy5,000$9.61$48,050.00View SEC Filing  
6/25/2015Raju S.K. ChagantiDirectorSell5,296$12.00$63,552.00View SEC Filing  
6/12/2015Raju S.K. ChagantiDirectorSell7,000$12.01$84,070.00View SEC Filing  
6/11/2015Raju S.K. ChagantiDirectorSell46,454$12.03$558,841.62View SEC Filing  
6/8/2015Raju S.K. ChagantiDirectorSell24,583$12.03$295,733.49View SEC Filing  
5/14/2015John PappajohnDirectorBuy5,000$10.74$53,700.00View SEC Filing  
3/17/2015John PappajohnDirectorBuy50,000$7.36$368,000.00View SEC Filing  
3/16/2015Edward J SitarCFOBuy1,000$6.99$6,990.00View SEC Filing  
12/16/2014John PappajohnDirectorBuy5,589$6.20$34,651.80View SEC Filing  
12/15/2014John PappajohnDirectorBuy3,634$6.14$22,312.76View SEC Filing  
12/11/2014John PappajohnDirectorBuy27,087$6.03$163,334.61View SEC Filing  
12/10/2014John PappajohnDirectorBuy5,773$5.96$34,407.08View SEC Filing  
12/9/2014John PappajohnDirectorBuy39,686$5.35$212,320.10View SEC Filing  
5/21/2014Edward SitarCFOBuy1,000$10.67$10,670.00View SEC Filing  
5/21/2014John PappajohnDirectorBuy50,000$10.31$515,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cancer Genetics (NASDAQ:CGIX)
Latest Headlines for Cancer Genetics (NASDAQ:CGIX)
Source:
DateHeadline
streetinsider.com logoCancer Genetics (CGIX) Partners with Roche's Ventana Medical Systems
www.streetinsider.com - May 16 at 12:42 PM
streetinsider.com logoCancer Genetics (CGIX) Partners with Roche's Ventana Medical Systems - StreetInsider.com
www.streetinsider.com - May 15 at 4:00 PM
finance.yahoo.com logoCancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to Ensure Market Access to Predictive Biomarker Test for New Immuno-Oncology (IO) Therapy for Advanced Bladder Cancer
finance.yahoo.com - May 15 at 12:50 PM
finance.yahoo.com logoEdited Transcript of CGIX earnings conference call or presentation 12-May-17 1:00pm GMT
finance.yahoo.com - May 12 at 9:48 PM
seekingalpha.com logoCancer Genetics' (CGIX) CEO Panna Sharma on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 4:48 PM
finance.yahoo.com logoInvestor Network: Cancer Genetics, Inc. to Host Earnings Call
finance.yahoo.com - May 12 at 4:48 PM
americanbankingnews.com logoCancer Genetics Inc (CGIX) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - May 12 at 12:14 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability
finance.yahoo.com - May 11 at 9:53 PM
finance.yahoo.com logoCancer Genetics reports 1Q loss
finance.yahoo.com - May 11 at 9:53 PM
streetinsider.com logoCancer Genetics (CGIX) Launches Multi-Gene Liquid Biopsy Test For Lung Cancer Patients - StreetInsider.com
www.streetinsider.com - May 9 at 8:20 AM
finance.yahoo.com logoCancer Genetics, Inc. Changes The Paradigm For Lung Cancer Monitoring – Launches Clinically Actionable, Multi-Gene, Liquid Biopsy Test For Lung Cancer Patients, Liquid::Lung-cfDNA™
finance.yahoo.com - May 8 at 10:08 AM
finance.yahoo.com logoCancer Genetics to Hold First Quarter 2017 Earnings Call on Friday, May 12th
finance.yahoo.com - May 5 at 4:28 PM
americanbankingnews.com logoCancer Genetics Inc (CGIX) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - May 1 at 5:46 PM
americanbankingnews.com logoCancer Genetics (CGIX) Given Daily News Impact Score of 0.04
www.americanbankingnews.com - April 30 at 4:11 PM
finance.yahoo.com logoETFs with exposure to Cancer Genetics, Inc. : April 27, 2017
finance.yahoo.com - April 27 at 4:43 PM
americanbankingnews.com logoCancer Genetics (CGIX) Getting Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 12:48 PM
globenewswire.com logoCancer Genetics, Inc. to Present at The Pioneers 2017 Conference Presented by Joseph Gunnar & Co., LLC - GlobeNewswire (press release)
globenewswire.com - April 25 at 4:05 PM
finance.yahoo.com logoCancer Genetics, Inc. to Present at The Pioneers 2017 Conference Presented by Joseph Gunnar & Co., LLC
finance.yahoo.com - April 25 at 12:15 PM
finance.yahoo.com logoCancer Genetics, Inc. Launches a Unique, Industry-Leading Panel That Provides Comprehensive & Precise Information for Immuno-Oncology Therapy Assessment & Patient Monitoring
finance.yahoo.com - April 24 at 9:40 AM
americanbankingnews.com logoVery Favorable News Coverage Very Likely to Affect Cancer Genetics (CGIX) Share Price
www.americanbankingnews.com - April 23 at 7:58 AM
americanbankingnews.com logoCancer Genetics (CGIX) Given News Impact Score of 0.25
www.americanbankingnews.com - April 20 at 6:15 PM
americanbankingnews.com logoCancer Genetics (CGIX) Getting Very Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 17 at 10:26 AM
americanbankingnews.com logoCancer Genetics Inc (CGIX) Short Interest Update
www.americanbankingnews.com - April 15 at 11:56 AM
americanbankingnews.com logoCancer Genetics (CGIX) Given News Sentiment Rating of 0.33
www.americanbankingnews.com - April 14 at 7:57 PM
globenewswire.com logoCancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development ... - GlobeNewswire (press release)
globenewswire.com - April 11 at 11:07 AM
finance.yahoo.com logoCancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
finance.yahoo.com - April 10 at 12:26 PM
americanbankingnews.com logo Analysts Anticipate Cancer Genetics Inc (CGIX) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 10 at 11:27 AM
finance.yahoo.com logoCancer Genetics, Inc. and Mendel.ai Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care
finance.yahoo.com - April 3 at 4:41 PM
finance.yahoo.com logoEdited Transcript of CGIX earnings conference call or presentation 23-Mar-17 1:00pm GMT
finance.yahoo.com - March 31 at 4:25 PM
finance.yahoo.com logoDon't Fight the Tape; Stock Going Higher
finance.yahoo.com - March 30 at 4:41 PM
globenewswire.com logoCancer Genetics, Inc. to Present at The MicroCap Conference on April 4th at 08:00 AM in New York City - GlobeNewswire (press release)
globenewswire.com - March 29 at 9:42 PM
finance.yahoo.com logoCANCER GENETICS, INC Financials
finance.yahoo.com - March 28 at 4:02 PM
americanbankingnews.com logoHC Wainwright Analysts Give Cancer Genetics Inc (CGIX) a $6.00 Price Target
www.americanbankingnews.com - March 27 at 2:49 PM
capitalcube.com logoCancer Genetics, Inc. :CGIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017
us.rd.yahoo.com - March 24 at 9:33 PM
finance.yahoo.com logoCancer Genetics and Therapix Biosciences Get Financial Boost
finance.yahoo.com - March 24 at 4:32 PM
biz.yahoo.com logoCANCER GENETICS, INC Files SEC form 8-K, Shareholder Director Nominations
biz.yahoo.com - March 24 at 4:32 PM
benzinga.com logoMid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide - Benzinga
www.benzinga.com - March 23 at 9:41 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Ford, PVH, Accenture, Orion ... - Nasdaq
www.nasdaq.com - March 23 at 9:41 PM
biz.yahoo.com logoQ4 2016 Cancer Genetics Inc Earnings Release - After Market Close
biz.yahoo.com - March 23 at 4:40 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update
finance.yahoo.com - March 23 at 4:40 PM
biz.yahoo.com logoCANCER GENETICS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financ
biz.yahoo.com - March 23 at 4:40 PM
americanbankingnews.com logoCancer Genetics Inc (CGIX) Posts Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - March 23 at 9:08 AM
americanbankingnews.com logoCancer Genetics Inc (CGIX) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 22 at 7:34 AM
finance.yahoo.com logoCancer Genetics, Inc. to Present at The MicroCap Conference on April 4th at 08:00 AM ET in New York City at the Essex House
finance.yahoo.com - March 20 at 2:55 PM
finance.yahoo.com logoCancer Genetics to Present at "A Future Without Cancer Conference" on Friday, March 17
finance.yahoo.com - March 13 at 12:42 PM
nasdaq.com logoCancer Genetics India Partners with CSIR-Centre for Cellular and ... - Nasdaq
www.nasdaq.com - February 24 at 4:25 PM
finance.yahoo.com logoCancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next Generation Sequencing Conference in India
finance.yahoo.com - February 23 at 4:13 PM
finance.yahoo.com logoCancer Genetics, Inc. to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
finance.yahoo.com - February 22 at 12:09 PM
biz.yahoo.com logoCANCER GENETICS, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 22 at 12:09 PM
biz.yahoo.com logoCANCER GENETICS, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 16 at 9:21 PM

Social

Chart

Cancer Genetics (CGIX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff